# Neuralink — Healthcare Investment Intelligence

> medical_device · Series E. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) with high-bandwidth electrodes for patients with paralysis or neurological impairments, having received FDA approval for human trials in May 2023 and implanted its first patient in January 2024.[1][2][4] The company, founded in 2016 by Elon Musk, has raised significant venture funding through multiple rounds, including substantial investments supporting clinical advancements and manufacturing expansion.[1]

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series E
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 15/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-21. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.